AbbVie Inc. ABBV
264.34
(0.78)
(0.29%)
as of 25 Sep
- Market cap
- $467.4B
- P/E
- 74.7×
Follow ABBV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
AbbVie Inc. (ABBV) Revenue growth
AbbVie Inc.'s revenue growth over the twelve months to 30 June 2026 was 10.4%, up 1.8 percentage points from fiscal 2025 (8.57%). Over the past ten years it has ranged from −6.44% (fiscal 2023) to 37.7% (fiscal 2020); the current reading is higher than 45% of that period. That is above the Drug Manufacturers General industry median of 6.79% and above the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 8.57% | 4.86 |
| FY2024 | 3.71% | 10.15 |
| FY2023 | −6.44% | (9.74) |
| FY2022 | 3.30% | (19.39) |
| FY2021 | 22.7% | (15.00) |
| FY2020 | 37.7% | 36.12 |
| FY2019 | 1.57% | (14.51) |
| FY2018 | 16.1% | 6.02 |
| FY2017 | 10.1% | (2.10) |
| FY2016 | 12.2% | (2.36) |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 10.2% | (2.27) |
| Mar 2026 | 12.4% | 2.39 |
| Dec 2025 | 10.0% | 0.94 |
| Sep 2025 | 9.10% | 2.45 |
| 42 more quarters | Free account |
Against its own ten years
Low −6.44%
High 37.7%
Ten-year median
10.1%
Current reading's percentile
45
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LLY Eli Lilly and Company compare | 49.6% |
| ABBV AbbVie Inc. | 10.4% |
| AMGN Amgen Inc. compare | 9.10% |
| AZN AstraZeneca PLC compare | 8.61% |
| JNJ Johnson & Johnson compare | 8.06% |
| GILD Gilead Sciences, Inc. compare | 5.52% |
| MRK Merck & Co., Inc. compare | 4.64% |
| NVS Novartis AG compare | 2.73% |
| PFE Pfizer Inc. compare | −0.21% |
| Drug Manufacturers General industry median | 6.79% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ABBV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement